These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 884936)

  • 21. [Clinical observations on the treatment of ischemic cardiac disease with a calcium antagonist: nifedipine].
    Bufalini AA; Bargero G; Botta M; Marzani MC; Montalenti P; Navazzotti R; Piccolini E; Marzani PC
    Arch Sci Med (Torino); 1980; 137(4):715-24. PubMed ID: 7247695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Physiopathological aspects of calcium metabolism at the myocardial level. Clinical experience with nifedipine].
    Ripa R; Frisoni B; Farabegoli E; Tisselli R; Tripodi G
    Boll Soc Ital Cardiol; 1978; 23(6):1079-82. PubMed ID: 261876
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical effect of O-betahydroxyethyl-rutosides (HR) in patients with occlusive arterial disease.
    Bielawiec M; Lukjan H; Grabowski R; Myśliwiec M; Korfel B
    Bibl Anat; 1977; (16 Pt 2):152-4. PubMed ID: 603503
    [No Abstract]   [Full Text] [Related]  

  • 24. [Vasomotor action of acetylcholine o peripheral occlusive arterial diseases (plethysmograpic findings on the leg during acetylcholine arteriosclerosis)].
    Dorigo B; Biti GP
    Minerva Cardioangiol; 1969 Oct; 17(10):724-9. PubMed ID: 5404965
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of functional changes in arteriosclerotic chronic obliterating peripheral arterial diseases (COPA) and Buerger's and Raynaud's diseases with pharmacological sympathicolysis, with or without indirect surgical treatment].
    Bagliani A; Borri P; Taborelli R
    Minerva Cardioangiol; 1973 Jun; 21(6):439-52. PubMed ID: 4720185
    [No Abstract]   [Full Text] [Related]  

  • 26. [On the treatment of "intermittent claudication" in chronic peripheral obliterating arteriopathies of the lower extremities caused by arteriosclerosis and Buerger's disease].
    Seghezzi R; Pedroni G; Borri P
    Chir Ital; 1967; 19():Suppl 2:222+. PubMed ID: 5190600
    [No Abstract]   [Full Text] [Related]  

  • 27. Peripheral arterial disease: drug therapy.
    Schwartz JB
    J Gend Specif Med; 2002; 5(4):16-20. PubMed ID: 12192882
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effect of 1-(4-oxyphenyl)-1-oxy-2-n-butylaminoethane sulfate on peripheral vascular diseases].
    Giulini SM; Agus GB; De Cristoforo A
    Minerva Cardioangiol; 1973 Jun; 21(6):434-8. PubMed ID: 4146376
    [No Abstract]   [Full Text] [Related]  

  • 29. [Nifedipine, a new coronaroactive drug].
    Avogadro BG; Cavanna M
    Clin Ter; 1975 Jun; 73(6):581-6. PubMed ID: 1139869
    [No Abstract]   [Full Text] [Related]  

  • 30. [Calcium antagonists in cardiologic therapy].
    Ripa R
    Minerva Med; 1978 Oct; 69(48):3323-5. PubMed ID: 724143
    [No Abstract]   [Full Text] [Related]  

  • 31. [Calcium antagonists in cardiologic therapy].
    Ripa R
    Minerva Cardioangiol; 1978 Nov; 26(11):757-9. PubMed ID: 724125
    [No Abstract]   [Full Text] [Related]  

  • 32. Diagnosis and treatment of occlusive peripheral arterial disease.
    Spittell JA
    Geriatrics; 1982 Jan; 37(1):57-67. PubMed ID: 7054056
    [No Abstract]   [Full Text] [Related]  

  • 33. [Experiences with solcoseryl in treatment of stage II peripheral arterial occlusive disease--assessment of clinical effectiveness].
    Horsch S; Claeys L
    Vasa Suppl; 1992; 35():151-2. PubMed ID: 1481024
    [No Abstract]   [Full Text] [Related]  

  • 34. [Clinical use of thymoxamine in peripheral arterial pathology].
    Ghiglino GC; Viacava A; Gori A; Misuri A; Lucertini G; Pelagatti M
    Clin Ter; 1983 Apr; 105(2):103-7. PubMed ID: 6222862
    [No Abstract]   [Full Text] [Related]  

  • 35. Beneficial effects of nifedipine on regional myocardial blood flow in patients with coronary artery disease.
    Malacoff RF; Lorell BH; Mudge GH; Holman BL; Idoine J; Bifolck L; Cohn PF
    Circulation; 1982 Jan; 65(1 Pt 2):I32-7. PubMed ID: 7053296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug treatment of peripheral vascular disease.
    Eberhardt RT; Coffman JD
    Heart Dis; 2000; 2(1):62-74. PubMed ID: 11728242
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ergometric studies and clinical observations in patients with coronary disease treated with nifedipine].
    Adamska-Dyniewska H; Atta W
    Kardiol Pol; 1977; 20(2):107-13. PubMed ID: 864905
    [No Abstract]   [Full Text] [Related]  

  • 38. [Controlled study of nifedipine in the treatment of Raynaud's phenomenon].
    Kahan A; Weber S; Amor B; Saporta L; Hodara M; Degeorges M
    Rev Rhum Mal Osteoartic; 1982 Apr; 49(5):337-43. PubMed ID: 6285445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Training by walking and drug therapy of peripheral arterial occlusive disease].
    Kiesewetter H; Blume J; Jung F; Gerhards M; Leipnitz G
    Vasa Suppl; 1987; 20():384-7. PubMed ID: 3321495
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effect of papaveroline on chronic, obliterating, peripheral arterial diseases].
    Sironi G; Benedetti G
    Minerva Cardioangiol; 1973 Apr; 21(4):257-63. PubMed ID: 4710122
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.